Voyager Therapeutics, Inc.

NASDAQ:VYGR

Biotechnology

Healthcare
$1.67 +2.35%

+$0.09 today

Market cap
$103.92M
Beta
1.25
P/E (TTM)
-1.9
EPS (TTM)
-$1.96
52W Low $2.83High $5.55

Volume 0.84M

Average 0.54M

Income Statement

Follow revenue through to earnings.

Revenue

$40.37M

FY 2025 · Annual

-49.5% YoY

Operating Income

-$131.84M

FY 2025 · Annual

Net Income

-$119.72M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.42M40.91M250.01M80M40.37M
Cost of Revenue73.79M55.76M92.17M00
Gross Profit(36.37M)(14.86M)157.84M80M40.37M
Gross Margin-97.2%-36.3%63.1%100.0%100.0%
Research & Development73.79M60.76M92.17M127.37M134.67M
Selling, General & Admin37.25M30.98M35.82M35.92M37.54M
Operating Expenses37.25M35.98M35.82M163.29M172.22M
Depreciation & Amortization5.17M6.19M4.44M4.73M4.06M
EBITDA(66.03M)(39.65M)138.18M(59.61M)(115.52M)
EBITDA Margin-176.5%-96.9%55.3%-74.5%-286.1%
Operating Income(73.62M)(50.84M)122.01M(83.29M)(131.84M)
Operating Margin-196.8%-124.3%48.8%-104.1%-326.6%
Interest Income01.79M11.72M18.33M10.62M
Interest Expense00000
Other Income / Expenses2.42M4.45M11.72M18.95M12.27M
Income Before Tax(71.2M)(46.39M)133.74M(64.34M)(119.58M)
Pre-Tax Margin-190.3%-113.4%53.5%-80.4%-296.2%
Income Tax Expense016K1.41M665K144K
Net Income(71.2M)(46.41M)132.33M(65M)(119.72M)
Net Margin-190.3%-113.4%52.9%-81.3%-296.5%
EPS (Basic)(1.75)(1.21)3.08(1.13)(2.04)
EPS (Diluted)(1.75)(1.21)2.97(1.13)(2.04)
Weighted Avg Shares37.67M38.36M43.02M57.67M58.69M
Weighted Avg Shares (Diluted)37.67M38.36M44.57M57.67M58.69M

VYGR Earnings Waterfall · TTM

NASDAQ:VYGR · Revenue to Net Income

Key Ratios

EPS$-1.98
Gross Margin-126.7%
Net Margin-526.7%
P/E Ratio-2.0
P/S Ratio39.8

Analysis

$36.5M of revenue converted into -$116.6M of net income for the selected period. Gross margin is -126.7% and net margin is -526.7%, showing how much revenue survives after costs and taxes. EPS is $-1.98, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
4Statement of changes in beneficial ownershipNov 3, 2026
4Statement of changes in beneficial ownershipNov 3, 2026
8-KCurrent reportOct 21, 2026

How much revenue does VYGR generate?

Voyager Therapeutics, Inc. (VYGR) reported $40.37M of revenue in fiscal 2025.

Is VYGR profitable?

Voyager Therapeutics, Inc. (VYGR) reported -$119.72M of net income, with a net margin of -296.5%.